Physician profile
Vinay Sharma
NPI 1164425237
$3,153.35
in general payments reported to CMS, 2019-2025
43 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $170 · 2021: $777 · 2022: $904 · 2023: $406 · 2024: $311 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $370.23 | 2021-2024 | Airsupra, Lynparza |
| Janssen Biotech, INC. | $272.42 | 2021-2024 | Erleada |
| Novartis Pharmaceuticals Corporation | $260.35 | 2021-2024 | |
| Glaxosmithkline, LLC. | $219.35 | 2019-2024 | Arexvy |
| Pfizer INC. | $166.13 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $154.86 | 2019-2021 | |
| Genentech USA, INC. | $148.35 | 2022 | |
| Genzyme Corporation | $125.00 | 2025 | |
| Janssen Pharmaceuticals, INC | $124.99 | 2019 | |
| Amgen INC. | $122.54 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $101.80 | 2023 | Libtayo |
| Mylan Specialty L.P. | $91.59 | 2020 | |
| Pharmaessentia USA Corporation | $82.99 | 2022-2023 | Besremi |
| Jazz Pharmaceuticals INC. | $68.89 | 2021 | |
| Merck Sharp & Dohme LLC | $64.84 | 2021-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.